The mTORC1 Inhibitor Everolimus Combined with R-CHOP-21 for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Safety and Efficacy Results of a Phase I and Feasibility Trial NCCTG 1085 (Alliance)

BACKGROUND: The PI3K/mTORC pathway is upregulated in diffuse large B-cell lymphoma (DLBCL) and can be targeted with the mTORC1 inhibitor everolimus. Everolimus has activity in relapsed DLBCL. These data provide the rationale to combine everolimus with standard R-CHOP-21. METHODS: The primary endpoin...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Lancet Haematol
Huvudupphovsmän: Johnston, Patrick B., LaPlant, Betsy, McPhail, Ellen, Habermann, Thomas M., Inwards, David J., Micallef, Ivana N., Colgan, Joseph P., Nowakowski, Grzegorz S., Ansell, Stephen M., Witzig, Thomas E.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2016
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4958393/
https://ncbi.nlm.nih.gov/pubmed/27374464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(16)30040-0
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk